| Name | FN-1501 |
| Description | FN-1501 is a potent FLT3 and CDK inhibitor (IC50s: 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively). FN-1501 also has anticancer activity. |
| In vitro | FN-1501 displays potent inhibitory activity against several tumor cells, such as MGC803, RS4;11, MCF-7, HCT-116, and NCI-H82 (GI50s of 0.37 ± 0.04, 0.05 ± 0.01, 2.84 ± 0.25, 0.09 ± 0.04, 0.11 ± 0.02 nM, respectively)[1]. |
| In vivo | FN-1501 shows potent antitumor activity and it also shows little cytotoxicity on normal lymphocyte cells (LD50: 185.67 mg/kg in ICR mice). FN-1501 (15. 30, or 40 mg/kg/d, i.v.) dose-dependently and obviously inhibits the growth of tumors in MV4-11-cell-inoculated-xenograft mice[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.64 mM), Sonication is recommended. DMSO : 150 mg/mL (347.63 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | FN-1501 | FN1501 | FN 1501 | Fms like tyrosine kinase 3 | FLT3 | Cyclin dependent kinase | Cluster of differentiation antigen 135 | CDK6/cyclinD1 | CDK6/cycD1 | CDK4/CyclinD1 | Cdk4/cyclin D1 | CDK2/CyclinA | cdk2/cyclin A | CDK | CD135 |
| Inhibitors Related | Ribociclib | Gilteritinib | Amantadine | 2-Chloropyrazine | Kojic acid | Sorafenib | Abemaciclib | Pexidartinib | 2,4,6-Trihydroxybenzoic acid | Brigatinib | Palbociclib | Sodium Oxamate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |